Carregant...
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Background: Renin angiotensin aldosterone system inhibitor (RAASi) therapy is part of the cornerstone of therapy for patients (pts) with cardiovascular disease including hypertension, CHF, and/or CAD, but use is often limited by the development of hyperkalemia. Patiromer (PAT) is a sodium (Na)-free...
Guardat en:
| Publicat a: | J Drug Assess |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764378/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658287 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|